In contrast, cancer cells later adapt to develop a resistance to TGF-β1-mediated growth inhibition by increasing expression of TGF-β1 antagonist, mutating the TGF-β1 receptor or inactivating the SMAD4 gene. Here, SMAD4 is linked to cancer.